Vimian Group AB (publ) (STO:VIMIAN)

Market Cap	16.44B
Revenue (ttm)	4.52B
Net Income (ttm)	254.63M
Shares Out	521.85M
EPS (ttm)	0.45
PE Ratio	70.52
Forward PE	24.47
Dividend	n/a
Ex-Dividend Date	n/a

Volume	86,327
Average Volume	858,105
Open	31.50
Previous Close	31.50
Day's Range	31.00 - 31.58
52-Week Range	31.08 - 47.30
Beta	1.56
RSI	29.31
Earnings Date	Jul 18, 2025

About Vimian Group AB

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the I...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 1,200
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: VIMIAN

Financial Performance

In 2024, Vimian Group AB's revenue was 374.80 million, an increase of 12.99% compared to the previous year's 331.70 million. Earnings were 18.50 million, an increase of 88.78%.

Financial numbers in EUR